Skip to content

Adolescent hayfever and quality of life

Cluster randomised controlled trial of an educational intervention for healthcare professionals into the management of school-age children with hayfever

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN95538067
Enrollment
264
Registered
2008-08-19
Start date
2008-08-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seasonal allergic rhinitis (hayfever) Respiratory Vasomotor and allergic rhinitis

Interventions

The randomisation is at the level of the general practice, i.e. the practices are the clusters. The health care professional intervention is a one day short course entitled 'Essential Asthma and All

Sponsors

Chief Scientist Office of the Scottish Executive Health Department (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Young people (both males and females) aged 12 - 18 years 2. Hayfever, defined by the presence of a documented clinician diagnosis in the patient's health record and any evidence of treatment used for allergic rhinitis

Exclusion criteria

Exclusion criteria: 1. Unable to give consent 2. Taking part in any other clinical trials involving treatment for allergic rhinitis

Design outcomes

Primary

MeasureTime frame
Difference in the validated Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score between the intervention and control groups at baseline and 3 and 6 weeks post-intervention.

Secondary

MeasureTime frame
1. Symptom scores, assessed using a visual analogue scale at 3 and 6 weeks post intervention 2. Overall assessment of seasonal allergic rhinitis symptoms compared with the previous season, assessed 6 weeks post intervention 3. Number of general practitioner and practice nurse consultations for hayfever; prescribed (from clinical records) and over-the-counter (from patients) medication data will be collected for cost-effectiveness comparison. Theses will be assessed at end of hayfever period (September 2009) 4. Examination performance, assessed at end of hayfever period (September 2009) 5. Assessment of change in clinical practice on completion of trial

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 31, 2026